Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
GENEVA, SWITZERLAND / ACCESSWIRE / December 5, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced its intent to progressively transition from a direct marketing and sales infrastructure for its commercial-stage assets to a partnership-based model. The Company believes that the transition will continue to enable more efficient patient access through leveraging external expertise and infrastructure. The Company intends to streamline its commercial operations and focus its resources on its R&D activities, paving the way for sustainable growth.
瑞士日內瓦/ACCESSWIRE/2023年12月5日/致力於爲特定特殊疾病、未被滿足的疾病和罕見疾病提供創新治療方案的生物製藥公司救濟治療控股有限公司(SIX: RLLF)(OTCQB: RLFTF)(OTCQB: RLFTY)(Relief,或公司)今天宣佈打算逐步從商業階段資產的直銷和銷售基礎設施過渡到合作伙伴關係基於的模型。該公司認爲,通過利用外部專業知識和基礎設施,過渡將繼續使患者能夠更有效地獲得服務。該公司打算簡化其商業運營,將資源集中在研發活動上,爲可持續增長鋪平道路。
Michelle Lock, interim chief executive officer of Relief, commented, "Our strategic pivot will enable us to reallocate resources towards our advancing R&D pipeline. It will also reinforce Relief's foundational strengths and historical business model, centered around drug development and the business-to-business (B2B) commercialization of our products." This decision primarily affects Relief's GOLIKE franchise, with the Company's other products historically licensed or distributed through third parties.
Relief臨時首席執行官米歇爾·洛克評論說:“我們的戰略支點將使我們能夠爲不斷髮展的研發渠道重新分配資源。它還將強化Relief的基礎優勢和歷史商業模式,以藥物開發和我們產品的企業對企業(B2B)商業化爲中心。”這個決定主要影響 Relief 的 GOLIKE 特許經營,公司的其他產品歷來是通過第三方許可或分銷的。
The Company remains committed to supporting the needs of patients currently benefiting from PKU GOLIKE and is exploring potential partnerships for the continued commercialization and expansion of its GOLIKE franchise and the expected commercial launch of RLF-OD032 in early 2026. PKU GOLIKE is currently marketed by Relief in the U.S., Italy, Germany, Austria and Switzerland, and is licensed to distribution partners in the UK, Spain, Portugal, Israel, Greece, Cyprus, Ecuador, and certain Middle Eastern countries. PKU GOLIKE shall remain commercially available in the U.S. via Relief's distribution arrangement with Pentec Health, Inc.
該公司仍然致力於支持目前受益於北大患者 GOLIKE 的需求 並正在探索潛在的合作伙伴關係,以使其GOLIKE的持續商業化和擴展 特許經營權以及 RLF-OD032 預計將於 2026 年初商業上市。PKU GOLIKE 目前由 Relief 在美國、意大利、德國、奧地利和瑞士銷售,並已獲得英國、西班牙、葡萄牙、以色列、希臘、塞浦路斯、厄瓜多爾和某些中東國家的分銷合作伙伴的許可。PKU GOLIKE 將通過 Relief 與 Pentec Health, Inc. 簽訂的分銷安排繼續在美國上市
Relief also remains actively engaged in optimizing the value of its development-stage pipeline, continuing the development of RLF-OD032 for phenylketonuria (PKU), RLF-TD011 for dermatological conditions, RLF‐100 (aviptadil) for pulmonary disorders, and Olpruva for metabolic disorders in Europe.
Relief 還繼續積極參與優化其研發階段產品線的價值,繼續在歐洲開發用於苯丙酮尿症 (PKU) 的 RLF-OD032、用於皮膚病的 RLF-TD011、用於肺部疾病的 RLF-100(aviptadil)和用於代謝性疾病的 Olpruva。
ABOUT RELIEF THERAPEUTICS
關於救濟療法
Relief Therapeutics is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief Therapeutics' portfolio offers a balanced mix of marketed, revenue-generating products, our proprietary, globally patented Physiomimic and TEHCLO platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare metabolic disorders, rare skin diseases and rare respiratory diseases. In addition, Relief Therapeutics is commercializing several legacy products via licensing and distribution partners. Relief Therapeutics' mission is to provide therapeutic relief to those suffering from rare diseases and is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Relief Therapeutics is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany and Monza, Italy. Relief Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, please visit our website or follow Relief Therapeutics on LinkedIn and Twitter.
Relief Therapeutics是一家處於商業階段的生物製藥公司,致力於推進治療模式,提高療效、安全性和便利性,從而使患有特定特殊疾病和罕見疾病的患者的生活受益。Relief Therapeutics的產品組合平衡地組合了已上市的創收產品、我們專有的全球專利Physiomimic和TEHCLO平台技術,以及由專注於三個核心治療領域的風險緩解資產組成的有針對性的臨床開發渠道:罕見代謝性疾病、罕見皮膚病和罕見呼吸道疾病。此外,Relief Therapeutics正在通過許可和分銷合作伙伴將幾種傳統產品商業化。Relief Therapeutics的使命是爲罕見病患者提供治療救濟,由一支由經驗豐富、經驗豐富的生物製藥行業領導者組成的國際團隊正在推進,他們擁有廣泛的研究、開發和罕見病專業知識。Relief Therapeutics總部位於日內瓦,並在瑞士巴萊爾納、德國美因河畔奧芬巴赫和意大利蒙扎設有辦事處。Relief Therapeutics在瑞士證券交易所上市,代碼爲RLF,在美國的OTCQB上市,股票代碼爲RLFTF和RLFTY。欲了解更多信息,請訪問我們的網站或在 LinkedIn 和 Twitter 上關注 Relief Therapeutics。
CONTACT:
聯繫:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
救濟治療控股有限公司
傑里米·梅寧
首席財務官
contact@relieftherapeutics.com
Disclaimer
免責聲明
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, including its ability to achieve its corporate, development and commercial goals, and other factors which could cause the actual results, financial condition, performance or achievements of Relief to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors, including whether the Relief's change in its business strategy will be successful and those described in Relief's filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC), could adversely affect Relief. Copies of Relief's filings with the SEC are available on the SEC EDGAR database at www.sec.gov. Relief does not undertake any obligation to update the information contained herein, which speaks only as of this date.
本新聞稿包含前瞻性陳述。前瞻性陳述涉及已知和未知的風險、不確定性,包括其實現企業、發展和商業目標的能力,以及可能導致Relief的實際業績、財務狀況、業績或成就與此類前瞻性陳述所表達或暗示的任何未來業績、業績或成就存在重大差異的其他因素。許多因素,包括救濟組織對其業務戰略的改變能否成功,以及Relief向瑞士證券交易所證券交易所和美國證券交易委員會(SEC)提交的文件中描述的因素,都可能對Relief產生不利影響。救濟向美國證券交易委員會提交文件的副本可在美國證券交易委員會的EDGAR數據庫中查閱,網址爲www.sec.gov。Relief 不承擔任何義務更新此處包含的信息,該信息僅代表截至該日期。
SOURCE: RELIEF THERAPEUTICS Holding SA
來源:救濟療法控股有限公司
譯文內容由第三人軟體翻譯。